These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 17645678)

  • 1. Economic evaluation of tegaserod vs. placebo in the treatment of patients with irritable bowel syndrome: an analysis of the TENOR study.
    Bracco A; Jönsson B; Ricci JF; Drummond M; Nyhlin H
    Value Health; 2007; 10(4):238-46. PubMed ID: 17645678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation.
    Tack J; Müller-Lissner S; Bytzer P; Corinaldesi R; Chang L; Viegas A; Schnekenbuehl S; Dunger-Baldauf C; Rueegg P
    Gut; 2005 Dec; 54(12):1707-13. PubMed ID: 16020489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of tegaserod on work and daily activity in irritable bowel syndrome with constipation.
    Reilly MC; Barghout V; McBurney CR; Niecko TE
    Aliment Pharmacol Ther; 2005 Sep; 22(5):373-80. PubMed ID: 16128674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of tegaserod in Chinese patients with constipation-predominant irritable bowel syndrome].
    Tegaserod Clinical Research Group
    Zhonghua Nei Ke Za Zhi; 2003 Feb; 42(2):88-90. PubMed ID: 12783702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Budget impact of tegaserod on a managed care organization formulary.
    Bloom MA; Barghout V; Kahler KH; Bentkover J; Kurth H; Gralnek IM; Spiegel BM
    Am J Manag Care; 2005 Apr; 11(1 Suppl):S27-34. PubMed ID: 15926761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome.
    Nyhlin H; Bang C; Elsborg L; Silvennoinen J; Holme I; Rüegg P; Jones J; Wagner A
    Scand J Gastroenterol; 2004 Feb; 39(2):119-26. PubMed ID: 15000272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tegaserod treatment for IBS: a model of indirect costs.
    Smith DG; Barghout V; Kahler KH
    Am J Manag Care; 2005 Apr; 11(1 Suppl):S43-50. PubMed ID: 15926763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipation.
    Müller-Lissner S; Holtmann G; Rueegg P; Weidinger G; Löffler H
    Aliment Pharmacol Ther; 2005 Jan; 21(1):11-20. PubMed ID: 15644040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome.
    Harish K; Hazeena K; Thomas V; Kumar S; Jose T; Narayanan P
    J Gastroenterol Hepatol; 2007 Aug; 22(8):1183-9. PubMed ID: 17688659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tegaserod: long-term treatment for irritable bowel syndrome patients with constipation in primary care.
    Layer P; Keller J; Mueller-Lissner S; Rüegg P; Loeffler H
    Digestion; 2005; 71(4):238-44. PubMed ID: 16024929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic evaluation of linaclotide for the treatment of adult patients with irritable bowel syndrome with constipation in the United States.
    Huang H; Taylor DC; Carson RT; Sarocco P; Friedman M; Munsell M; Blum SI; Menzin J
    J Med Econ; 2015 Apr; 18(4):283-94. PubMed ID: 25333331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of linaclotide compared to antidepressants in the treatment of irritable bowel syndrome with constipation in Scotland.
    Fisher M; Walker A; Falqués M; Moya M; Rance M; Taylor D; Lindner L
    Eur J Health Econ; 2016 Dec; 17(9):1091-1100. PubMed ID: 26728984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A trial-based economic evaluation of peppermint oil for the treatment of irritable bowel syndrome.
    Weerts ZZRM; Essers BAB; Jonkers DMAE; Willems JIA; Janssen DJPA; Witteman BJM; Clemens CHM; Westendorp A; Masclee AAM; Keszthelyi D
    United European Gastroenterol J; 2021 Nov; 9(9):997-1006. PubMed ID: 34468079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does co-administration of a non-selective opiate antagonist enhance acceleration of transit by a 5-HT4 agonist in constipation-predominant irritable bowel syndrome? A randomized controlled trial.
    Foxx-Orenstein AE; Camilleri M; Szarka LA; McKinzie S; Burton D; Thomforde G; Baxter K; Zinsmeister AR
    Neurogastroenterol Motil; 2007 Oct; 19(10):821-30. PubMed ID: 17539894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial.
    Chey WD; Paré P; Viegas A; Ligozio G; Shetzline MA
    Am J Gastroenterol; 2008 May; 103(5):1217-25. PubMed ID: 18477346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tegaserod maleate in the treatment of irritable bowel syndrome: a clinical review.
    Rivkin A
    Clin Ther; 2003 Jul; 25(7):1952-74. PubMed ID: 12946544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of tegaserod on recto-sigmoid tonic and phasic activity in constipation-predominant irritable bowel syndrome.
    Di Stefano M; Miceli E; Mazzocchi S; Tana P; Missanelli A; Corazza GR
    Am J Gastroenterol; 2007 Aug; 102(8):1720-6. PubMed ID: 17521397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of withdrawing tegaserod treatment in comparison with continuous treatment in irritable bowel syndrome patients with abdominal pain/discomfort, bloating and constipation: a clinical study.
    Bardhan KD; Forbes A; Marsden CL; Mason T; Short G
    Aliment Pharmacol Ther; 2004 Jul; 20(2):213-22. PubMed ID: 15233702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, tolerability and satisfaction with tegaserod therapy in Asia-Pacific patients with irritable bowel syndrome with constipation.
    Fock KM; Wagner A;
    J Gastroenterol Hepatol; 2007 Aug; 22(8):1190-8. PubMed ID: 17524039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tegaserod is safe, well tolerated and effective in the treatment of patients with non-diarrhoea irritable bowel syndrome.
    Fried M; Beglinger C; Bobalj NG; Minor N; Coello N; Michetti P;
    Eur J Gastroenterol Hepatol; 2005 Apr; 17(4):421-7. PubMed ID: 15756094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.